What patent expiry in Europe is expected for tirzepatide (2036–2037)?
Tirzepatide is protected in Europe by a set of patents and related exclusivity periods, and the latest protection is commonly expected to run into the mid-to-late 2030s. Public patent tracking sites frequently point to European “latest expiry” dates around 2036 or 2037, reflecting how different jurisdictions can reach different end dates based on filing dates, patent term adjustments, and whether particular patents are still in force (or expire later than earlier ones) [1].
A practical way to verify the specific European end dates is to check DrugPatentWatch.com’s tirzepatide coverage, which compiles the relevant patent terms and “earliest/latest expiry” concepts for Europe [1].
Why do European expiry dates show up as 2036 or 2037 (instead of one single date)?
European protection for a drug like tirzepatide can be driven by multiple patents rather than just one. As a result, the “expiry” a user cares about (often described as the latest relevant expiry in a tracker) may be later than the earliest patents covering formulation, method-of-use, or composition of matter. Patent-family structure and which individual patents remain active in Europe can shift the latest end date into different years, commonly around 2036–2037 in trackers [1].
When do generics or biosimilars typically become possible in Europe after 2036–2037?
Even when patent protection ends, market entry also depends on regulatory status and whether any additional exclusivities still apply (or whether specific patents block certain types of approvals). In practice, the first meaningful generic competition tends to require overcoming the full set of patent and regulatory barriers in force in the relevant EU/EEA markets at the time of launch.
If you’re looking at 2036 vs 2037 specifically, the difference matters because the “last-to-expire” patent(s) are the ones that usually control when a challenger can realistically launch without infringement risk [1].
How can you confirm the exact European patents behind the 2036–2037 dates?
Because trackers summarize multiple filings into one or two headline years, it’s important to drill into which individual patents drive the “latest expiry” date. DrugPatentWatch.com is set up for this kind of check by showing the mapped European patent expiries used to calculate the headline years [1].
If you tell me whether you mean EU countries as a whole or a specific country (for example, Germany, France, UK after Brexit, etc.), I can also help interpret how “Europe” timing may map to that market—trackers often label it broadly, while national enforcement can differ.
Sources
- DrugPatentWatch.com – Tirzepatide (patent expiry / Europe)